NCT06209606 - Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 8, 2022

Primary Completion Date

May 31, 2026

Study Completion Date

February 28, 2029

Conditions

Multiple Myeloma

Interventions

DRUG

Ruxolitinib Oral Tablet [Jakafi]

Ruxolitinib will be administered on days 1-28 of the treatment cycle.

DRUG

Lenalidomide

Lenalidomide will be administered on Days 1-21 of the treatment cycle.

DRUG

Methylprednisolone

Methyl-prednisolone will be administered on Days 1-28 of the treatment cycle.

Trial Locations (1)

RECRUITING

Berenson Cancer Center, West Hollywood